Many obese people with type 2 diabetes develop non-alcoholic fatty liver disease, which may progress to liver fibrosis. EndoBarrier gastrointestinal liner is an innovative interventional treatment option for type 2 diabetic patients, which could affect diabetes associated liver disease.
Press Releases
3/27
3/7
GI Dynamics Announces Close of Second Tranche of Placement – AUD ~$1m
BOSTON and SYDNEY — 8 March 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing...
2/27